MedTrace Logo

Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects

NCT06832540 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-11-17

No results posted yet for this study

Summary

Mass Balance Study of \[14C\] TJ0113 in Healthy Chinese Subjects

Conditions

  • Healthy Chinese Subjects

Interventions

DRUG

[14C]TJ0113

Subjects will receive a single oral dose of approximately 200 mg/100 μCi of the oral formulation of \[14C\] TJ0113 under fasted conditions.

Sponsors & Collaborators

  • Hangzhou PhecdaMed Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-19
Primary Completion
2025-03-05
Completion
2025-03-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06832540 on ClinicalTrials.gov